Genmab A (GMAB) Net Cash Flow (2018 - 2026)
Genmab A (GMAB) posted Net Cash Flow of -$183.0 million for Q1 2026, down 148.93% on a QoQ basis from $374.0 million in Q3 2025, and down 179.22% year-over-year from $231.0 million in Q1 2025.
Genmab A (GMAB) Net Cash Flow (2018 - 2026) Analysis & Trends
Genmab A's Net Cash Flow history runs 7 years deep, the most recent figure standing at -$183.0 million for Q1 2026.
- Quarterly Net Cash Flow fell 179.22% year-over-year to -$183.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.0 million (up 102.24% YoY) and the FY2025 annual result came in at $332.0 million, up 137.43% from the prior year.
- Net Cash Flow was -$183.0 million for Q1 2026 at Genmab A, down from $374.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $374.0 million in Q3 2025 and bottomed at -$2.0 billion in Q4 2024.
- A 4-year average of -$542.3 million and a median of -$183.0 million in 2026 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow slumped 634.67% — and 2025, when it jumped 403.95%.
- Genmab A's Net Cash Flow stood at -$274.0 million in 2023, then slumped by 634.67% to -$2.0 billion in 2024, then jumped by 118.58% to $374.0 million in 2025, then tumbled by 148.93% to -$183.0 million in 2026.
- Business Quant data shows GMAB's Net Cash Flow at -$183.0 million in Q1 2026, $374.0 million in Q3 2025, and -$87.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | -183.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.00 Mn |
| Mar 31, 2026 | -183.00 Mn |
| Sep 30, 2025 | 374.00 Mn |
| Sep 30, 2025 | 374.00 Mn |
| Jun 30, 2025 | -87.00 Mn |
| Jun 30, 2025 | -87.00 Mn |
| Mar 31, 2025 | 231.00 Mn |
| Mar 31, 2025 | 231.00 Mn |
| Dec 31, 2024 | -2.01 Bn |
| Dec 31, 2024 | -2.01 Bn |
| Sep 30, 2024 | -1.29 Bn |
| Sep 30, 2024 | -1.29 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Mar 31, 2024 | -76.00 Mn |
| Mar 31, 2024 | -76.00 Mn |
| Dec 31, 2023 | -274.00 Mn |
| Dec 31, 2023 | -274.00 Mn |
| Sep 30, 2020 | 5,097.00 |
| Sep 30, 2020 | 5,097.00 |